A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections

On the basis of monotherapy for intra-abdominal infection, the investigators are conducting this study to identify the difference of drug efficacy between ampicillin/sulbactam and moxifloxacin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intra-abdominal Infection Infections Intraabdominal Infections

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Kaohsiung Medical University Hospital, Department of Emergency Medicine/Surgery

Kaohsiung, Taiwan, 804

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients diagnosed of complicated intra-abdominal infection need surgical treatment

Exclusion criteria

patients diagnosed of intra-abdominal infection receive non-operative management
patients with known allergic history of fluoroquinolone
Severe, life threatening disease with a life expectancy of < 48 h or APS and APACHE scores of > 35

Treatment and study plan

moxifloxacin

Drug

moxifloxacin 400mg once daily (IV form, 60minutes)

ampicillin/sulbactam

Drug

ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)

Primary outcomes

clinical response at test-of-cure visit

Time frame: test of cure: 10-14 days after initial treatment

Sponsors and collaborators

Lead sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Other

Registry information

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Aug 6, 2009
Registry last updated: Aug 2, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed